Casey R Johnson1, Daniel V Dudenkov2, Kristin C Mara3, Philip R Fischer4, Julie A Maxson5, Tom D Thacher5. 1. Department of Pediatric and Adolescent Medicine, Mayo Clinic, Rochester, MN. Electronic address: johnson.casey2@mayo.edu. 2. Department of Internal Medicine, Mayo Clinic, Jacksonville, FL. 3. Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, MN. 4. Department of Pediatric and Adolescent Medicine, Mayo Clinic, Rochester, MN. 5. Department of Family Medicine, Mayo Clinic, Rochester, MN.
Abstract
OBJECTIVE: To determine the relationship between 25-hydroxyvitamin D (25[OH]D) values and subsequent cancer incidence and mortality. PATIENTS AND METHODS: We identified all adult patients living in Olmsted County, Minnesota, between January 1, 2005, and December 31, 2011, who had at least 1 25(OH)D measurement and no prior diagnosis of cancer. Cancer outcomes were retrieved starting 30 days after 25(OH)D measurement and until patients' final clinical visit as an Olmsted County resident; December 31, 2014; or death. Cox proportional hazards regression was used to analyze data. RESULTS: A total of 8700 individuals had a 25(OH)D measurement and no history of cancer, with a mean ± SD 25(OH)D value of 29.7±12.8 ng/mL (to convert to nmol/L, multiply by 2.496). The mean ± SD age was 51.5±16.4 years, and most were women (78.1%; n=6796) and White (85.7%; n=7460). A total of 761 individuals developed cancer (skin cancer, n=360; nonskin cancer, n=401) during a median follow-up of 4.6 (interquartile range, 3.4-6.1) years. Compared with participants with 25(OH)D values of 20 to 50 ng/mL (reference group), those with 25(OH)D values less than 12 ng/mL had a greater nonskin cancer incidence (hazard ratio [HR], 1.56; 95% CI, 1.03 to 2.36; P=.04) after adjustment. There was no association between 25(OH)D values and total cancer or skin cancer incidence. Compared with individuals from the reference group, 25(OH)D levels less than 12 ng/mL (HR, 2.35; 95% CI, 1.01 to 5.48; P=.047) and 12 to 19 ng/mL (HR, 2.10; 95% CI, 1.05 to 4.22; P=.04) were associated with increased cancer mortality. CONCLUSION: Low 25(OH)D levels were associated with increased risk for incident nonskin cancer and cancer-related mortality.
OBJECTIVE: To determine the relationship between 25-hydroxyvitamin D (25[OH]D) values and subsequent cancer incidence and mortality. PATIENTS AND METHODS: We identified all adult patients living in Olmsted County, Minnesota, between January 1, 2005, and December 31, 2011, who had at least 1 25(OH)D measurement and no prior diagnosis of cancer. Cancer outcomes were retrieved starting 30 days after 25(OH)D measurement and until patients' final clinical visit as an Olmsted County resident; December 31, 2014; or death. Cox proportional hazards regression was used to analyze data. RESULTS: A total of 8700 individuals had a 25(OH)D measurement and no history of cancer, with a mean ± SD 25(OH)D value of 29.7±12.8 ng/mL (to convert to nmol/L, multiply by 2.496). The mean ± SD age was 51.5±16.4 years, and most were women (78.1%; n=6796) and White (85.7%; n=7460). A total of 761 individuals developed cancer (skin cancer, n=360; nonskin cancer, n=401) during a median follow-up of 4.6 (interquartile range, 3.4-6.1) years. Compared with participants with 25(OH)D values of 20 to 50 ng/mL (reference group), those with 25(OH)D values less than 12 ng/mL had a greater nonskin cancer incidence (hazard ratio [HR], 1.56; 95% CI, 1.03 to 2.36; P=.04) after adjustment. There was no association between 25(OH)D values and total cancer or skin cancer incidence. Compared with individuals from the reference group, 25(OH)D levels less than 12 ng/mL (HR, 2.35; 95% CI, 1.01 to 5.48; P=.047) and 12 to 19 ng/mL (HR, 2.10; 95% CI, 1.05 to 4.22; P=.04) were associated with increased cancer mortality. CONCLUSION: Low 25(OH)D levels were associated with increased risk for incident nonskin cancer and cancer-related mortality.
Authors: Elizabeth J Williamson; Dallas R English; Alicia K Heath; Allison M Hodge; Peter R Ebeling; Darryl W Eyles; David Kvaskoff; Daniel D Buchanan; Graham G Giles Journal: Cancer Epidemiol Biomarkers Prev Date: 2019-03-06 Impact factor: 4.254
Authors: Marjorie L McCullough; Emilie S Zoltick; Stephanie J Weinstein; Veronika Fedirko; Molin Wang; Nancy R Cook; A Heather Eliassen; Anne Zeleniuch-Jacquotte; Claudia Agnoli; Demetrius Albanes; Matthew J Barnett; Julie E Buring; Peter T Campbell; Tess V Clendenen; Neal D Freedman; Susan M Gapstur; Edward L Giovannucci; Gary G Goodman; Christopher A Haiman; Gloria Y F Ho; Ronald L Horst; Tao Hou; Wen-Yi Huang; Mazda Jenab; Michael E Jones; Corinne E Joshu; Vittorio Krogh; I-Min Lee; Jung Eun Lee; Satu Männistö; Loic Le Marchand; Alison M Mondul; Marian L Neuhouser; Elizabeth A Platz; Mark P Purdue; Elio Riboli; Trude Eid Robsahm; Thomas E Rohan; Shizuka Sasazuki; Minouk J Schoemaker; Sabina Sieri; Meir J Stampfer; Anthony J Swerdlow; Cynthia A Thomson; Steinar Tretli; Schoichiro Tsugane; Giske Ursin; Kala Visvanathan; Kami K White; Kana Wu; Shiaw-Shyuan Yaun; Xuehong Zhang; Walter C Willett; Mitchel H Gail; Regina G Ziegler; Stephanie A Smith-Warner Journal: J Natl Cancer Inst Date: 2019-02-01 Impact factor: 13.506
Authors: Edward Giovannucci; Yan Liu; Eric B Rimm; Bruce W Hollis; Charles S Fuchs; Meir J Stampfer; Walter C Willett Journal: J Natl Cancer Inst Date: 2006-04-05 Impact factor: 13.506
Authors: Kun Zhu; Matthew Knuiman; Mark Divitini; Joseph Hung; Ee Mun Lim; Brian R Cooke; John P Walsh Journal: Nutr Res Date: 2019-03-21 Impact factor: 3.315
Authors: Vasiliki I Dimitrakopoulou; Konstantinos K Tsilidis; Philip C Haycock; Niki L Dimou; Kawthar Al-Dabhani; Richard M Martin; Sarah J Lewis; Marc J Gunter; Alison Mondul; Irene M Shui; Evropi Theodoratou; Katharina Nimptsch; Sara Lindström; Demetrius Albanes; Tilman Kühn; Timothy J Key; Ruth C Travis; Karani Santhanakrishnan Vimaleswaran; Peter Kraft; Brandon L Pierce; Joellen M Schildkraut Journal: BMJ Date: 2017-10-31